Enterprise Value
62.9M
Cash
22.92M
Avg Qtr Burn
-15.17M
Short % of Float
1.31%
Insider Ownership
12.07%
Institutional Own.
66.19%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Govorestat (AT-007) Details Galactosemia | Phase 3 Data readout | |
AT-001 Details Genetic disorder, Hemophilia, Diabetic cardiomyopathy Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Govorestat (AT-007) Details Sorbitol dehydrogenase deficiency | Phase 3 Data readout | |
Govorestat (AT-007) Details Congenital disorder of glycosylation, Phosphomannomutase 2 deficiency | Phase 2 Update | |
AT-003 Details Diabetic retinopathy | Phase 1 Update | |
AT-104 Details Leukemia, B-cell acute lymphoblastic leukemia, T-cell lymphoma | Failed Discontinued |